secwatch.observer — SEC 8-K summary
======================================

Issuer:     SpyGlass Pharma, Inc. (SGP)
CIK:        0001778922
Form:       8-K
Filed at:   2026-05-14T20:15:16+00:00
Accession:  0001778922-26-000033
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SpyGlass Pharma reports Q1 loss of $13.8M; Phase 1/2 BIM-IOL data shows 98% drop-free, 34% IOP reduction
--------------------------------------------------------------------------------

- Net loss of $13.8M ($0.69/share) vs $8.8M loss in Q1 2025; R&D expenses $8.5M, G&A $6.9M.
- Cash & investments $251M as of Mar 31, 2026, funded through 2028 after $172.5M IPO in Feb 2026.
- Phase 1/2 BIM-IOL 12-mo data: 98% drop-free, 34% mean IOP reduction from baseline at 78-mcg dose.
- Phase 3 registrational trials SGP-005 and SGP-006 continue; enrollment completion expected in 2027.
- Bimatoprost Drug Ring (BIM-DRS) first-in-human trial on track to start H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1778922/000177892226000033/0001778922-26-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1778922/000177892226000033/sgp-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001778922-26-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer